US IP Index Based On 'Flawed' Assumptions, Claim Indian Pharma Firms
Executive Summary
Indian drug makers have blasted the US Chamber of Commerce’s Global Innovation Policy Center over its International IP Index, saying its compilation is based on a “flawed” assumption that stronger patents drive greater innovation, and that it ignores individual national concerns.
You may also be interested in...
Indian Firms Push For Favorable USTR IPR Review
It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.
India Upholds Prevnar 13 Patent In Big Win For Pfizer
India has awarded Pfizer a patent for its blockbuster pneumonia vaccine Prevnar13, handing the pharmaceutical giant a big victory in a case which has been closely watched as a key test of the country’s patentability criteria.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.